Khairy et al 1 are to be commended for their presentation of data examining the effects of implantable cardioverter-defibrillators (ICDs) in patients with tetralogy of Fallot. The management of the risk of sudden cardiac death in such patients remains a major problem for the physicians caring for patients with congenital heart disease (CHD). We feel, however, that enthusiasm for ICD therapy in CHD should be tempered by the current lack of evidence of absolute benefit and clear evidence of device-related physical and psychological morbidity.
